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Abstract
Individual cancers, even of the same cell type, express unique arrays of distinctive tumor antigens,
requiring accurate laboratory measurement of induced immunity against them problematic.
Fluorescently tagged reagents (dextramers) that selectively engage clonal T-cell receptors (TCR) can
cytofluorographically quantify both frequency and avidity antigen-specific T-cells, but cannot be
synthesized without prior identification of the relevant antigen. Since clinically evident tumors may
contain as many as 300 unique point mutations capable of generating a large number of uniquely
antigenic proteins, and since procurement of such information for each cancer is currently unrealistic, it
is presently only possible to assess responses to anti-cancer immunotherapy by clinical determination of
estimation of the tumor burden capacity. Therefore, there is a need to develop methodology that can
quantify the collective anti-tumor T-cell response, without prior identification of the full array of
expressed tumor antigens. We have developed a practical high-resolution method to measure antigenspecific CD8 T-cell responses, via T-cell proton extrusion, an immediate result of selective TCR
engagement by antigen presenting cells. The fluorescent emission characteristics of hydroxypyrene
trisulfonate (HPTS) correlate with solution-phase proton concentrations, manifesting as increased
emission signals. We exploit this TCR characteristic within the context of T-cell activation and show
that stimulation with anti-CD3 immunoglobulin stimulates measureable TCR to release protons to a
significantly higher degree than unengaged TCR (p<0.001), both mouse and human systems. Specific
mouse CD8 T-cell responses to an exogenous tumor antigen (the eight amino acid derivative SIINFEKL
of transfected ovalbumin) and human CD8 T-cell responses to a melanoma-associate tissue antigen
(MART-1) differed from control (p<0.001). Human CD8 T-cell responses to MART-1 peptide,
presented by dendritic antigen presenting cells (DC) could be similarly distinguished from that to
control peptide (gp100), even when the frequency of MART-1 responsive CD8 T-cells was titrated
down from 23 percent to 1% (p<0.001), as measured in parallel by dextramers. When implemented in a
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tumor-responsive animal model, treatment groups showed higher emission intensities compared to
control groups at time points. These preliminary results confirm the practicality of real-time assessment
of antigen-specific TCR engagement, by proton release, a methodology which may become applicable
to T-cell responses to any collective group of antigens.
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Background
The role of immune cells in the development or regression of cancer has been a subject of
investigation for decades and the importance of the innate and adaptive immune systems in tumor
regression have provided the rationale for modern immunotherapy and cancer vaccines. The
introduction of checkpoint inhibitors, along with newer immunotherapeutic targets, has ushered in a
new era in cancer treatment strategy. Despite the promising circumstances, our ability to predict or
assess whether a patient is capable of responding to such newer agents remains inconsistent. Significant
focus is needed on developing consistent and standardized methods to evaluate CD8 T-cell responses to
administered therapies, and such efforts are not limited to the field of cancer therapy.1,2 The principle of
developing surrogate endpoints based on immunological readouts for every patient can have tremendous
advantages in navigating treatment strategies, especially if such information can be obtained prior to a
clinically observed outcome.
At the time of this study, there exist no more than 15 publications devoted to the subject of
“immunological monitoring” within the context of cancer since 1978. Studying the elements of an
immune response within different oncological frameworks therefore deserves more attention as the
majority of efforts thus far have focused on predicting immunological rejection within the field of organ
transplants. As cancer incidence rises, the utility of such data becomes increasingly relevant as newer
therapies become available and costs for developing improved strategies continue to escalate.3
Current approaches to assessing T-cell activation have remained rather consistent, with little
innovation, over the past few decades. The traditional approaches largely rely on measuring cell
proliferation, cytotoxicity or cytokine release. However, the probes used in such studies involve a small
group of model antigens that are “tumor-associated” for the relevant cancer and have been isolated and
well studied over time. The domineering fallback of such a dependency lies precisely in the disregard
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of the more immense cohort of antigens that are unknown or undefined and are arguably more relevant
to the immune surveillance profiles of each patient. The uniqueness of each patient’s tumor and immune
response therefore has been consistently assessed using artificial probes or reductionist assumptions that
have failed to prove consistency or clinical utility over time. Though readouts such as cytokinemediated amplification or cytotoxicity are theoretically valid approaches to determine the reactivity of a
patient’s CD8 T-cells, newer approaches need to be developed that look towards the use of undefined
sets of antigens to determine the state of a patient’s treatment response. Our aim is thus to develop an
approach that seeks to reconcile the need to identify causative antigens with an assay system that is
capable of measuring early signs of immunological activation in CD8 T-cells that can unfailingly be
identified in every patient.
Traditional Methods of Immunological Monitoring:
Enzyme-linked Immunospot (ELISPOT), cytokine flow cytometry, and tetramer or dextramer
positivity are among the most widely available and utilized approaches. Though ELISPOT is the most
frequently used method of detecting the number of reactive CD8 T-cells in patient samples, it was not
shown to correlate effectively with the other aforementioned techniques in a recent cancer vaccination
trial.4 This limited concordance suggests that the frequency of circulation of reactive populations of
cells may not be adequate enough for detection and that perhaps the vaccinations themselves could have
failed to elicit robust responses as well.
A longstanding immunological monitoring trial that spanned twelve academic centers, from five
European countries, concluded that our capability of assaying antigen specificity is extremely variable
and made recommendations for standardizing protocols.5 A cited reason for the inter-center variability
included the differing yield of assayable T-cells at each institution, along with inconsistent levels of
background noise with each readout strategy. Specifically, the study encountered difficulties with
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baseline spot numbers of ELISPOT testing and was unable to correlate to distinct variables or
outcomes of the study.
Intracellular cytokine analysis with flow cytometry and structural probes such as MHC tetramers
or dextramers are also various methods charged with the universal challenge of developing a consistent
assessment or readout from inconsistent starting material, such as the variable yield of CD8 T-cells seen
in different patients. Both approaches require standardized protocols and quality control assessments
prior to use, which can dictate the interpretation of results. For example, even factors such as staining on
ice compared to room temperature affect the avidity of a tetramer-TCR interaction as the ensuing results
can be influenced by background interactions. This has tremendous consequences for inter-institutional
variability and consistency in the acquired results. Tetramer or dextramer analysis also has a crucial
dependence on identifying the three-dimensional structure of immunodominant epitopes for TCR
engagement, which is an insurmountable logistical challenge considering the innumerable tumor
associated antigens seen in cancer patients.
Biophysics of Activation: Calcium flux and Proton Extrusion
Calcium flux, which represents the intracellular signaling cascade in the T-cell, is a well studied
and characterized as a marker of immune activation.6 Calcium ions are released from intracellular stores
during activation, mainly for purposes of secondary cellular signaling, and such stores may additionally
induce an influx of exogenous calcium through selective channels on the cell membrane.7 These signals
are essential for both short-term and longer-term processes such as cell motility, which can halt and can
promote a more stable immunological synapse, or differentiation into effector or memory phenotype. It
has been observed that even calcium ion flux can have variable patterns and manifestations depending
on the biophysical interactions that occur in the vicinity of the TCR. Under fully activating conditions
for example, the kinetics of the calcium ion changes resembles a sharp increase followed by a smooth
plateau. Even a small disturbance of the full signal can result in a delay or loss of cellular activation or
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proliferation and hence indicates the importance of sustained calcium signaling with respect to
cellular metabolic processes. The importance of a sustained calcium signal was shown to enable
transcription and its resulting processes, including downstream protein synthesis.8
Prior to activation, T-cells have low rates of cellular metabolic activity, though once activated,
undergo antigen-specific differentiation, optimize cytotoxic processes, and engage in paracrine signaling
via cytokine secretion. Downstream to the biophysical changes that occur such as calcium or proton
signals, other signaling pathways can be activated such as the MAP kinase pathway via RAS and RAF.
Costimulatory proteins such as the cytokine receptors or B7 can also contribute to T-cell activation.9,10
Such activities require significant biosynthetic efforts and hence rely on energy utilization and cellular
respiration. Extracellular acidification or proton flux is related to the catabolic pathways that seek to
generate ATP at the onset of cellular activation.11,12 Extracellular acidification is largely recognized as a
byproduct of lactic acid production within a cell and a profound increase can be indicative of
intracellular changes associated with ATP utilization.13 Such measurements can enable the identification
of bioenergetic states associated with environmental-induced alterations in cellular physiology and even
empower drug discovery efforts.
Rabinowitz and colleagues compared acid release, calcium flux, and T-cell proliferation
responses to a variety of different stimulating ligands.14 Their study noted that significantly greater
concentrations of antagonistic ligands or antibodies were needed to block the early events associated
with T-cell activation such as proton release or calcium flux. They were the first to propose that a
hierarchy exists within T-cell signaling in which various stages of activation correlate to the degree of a
ligand’s affinity and T-cell receptor engagement.
Use of model antigens
Classical approaches to predicting clinical responses have relied on delayed-type
hypersensitivity approaches to help provide some measure of CD4 or CD8 reactivity.15-17 As mentioned
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previously there is a reliance on T-cell defined antigens, which have shown to be poor correlates of
post-therapy outcomes. Such efforts therefore have a poor track record in developing surrogate
measures of the overall cellular immune response to therapy due to low precision, sensitivity, and
relevance to the library of unclassified antigens encountered by a host’s immune system. Tyronsinase,
MART-1, and gp100 are widely expressed in melanoma, for instance, but are also proteins associated
with normal tissues. Other melanoma probes include MAGE1, GAGE, and NY-ESO-1, all of which are
also expressed in normal or neoplastic testicular and placental tissue. Therefore, the model antigens
available to us are theoretically incapable of outputting tumor-specific trends for every patient. Some of
the most commonly cited disadvantages to such approaches include the requirement to know and
identify a peptide epitope and restricting allele, both of which require a significant level of technical
expertise (i.e. protein folding conditions) to drive the construction of specific peptide:MHC multimers,
which demonstrates how the evaluation of single or few epitopes may not provide a complete picture of
the total immune response to the gamut of tumor antigens.18
Although MART-1 positivity is sometimes reported to correlate to tumor regression, Saleh and
colleagues indicated that such an observation was restricted to tumor antigen-loss circumstances.19 It
was nevertheless acknowledged that immune responses to this specific antigen may be insufficient to
affect survival in patients with progressively-advanced disease. This is intuitive in the sense that such
patients may have a complex and diverse repertoire of tumor-associated antigens and therefore trying to
correlate a single, epitope-specific CD8 cell expansion to clinical tumor regression may not be a
consistent strategy of deciphering a patient’s immune response. In fact, it was shown that even though a
modified gp100 peptide vaccination could correlate with the expansion of a peptide-specific CD8
population expansion, not all of these expanded cells were shown to be functionally responsive with
respect to cytokine secretion and there was a lack of tumor regression in the trialed patients.20
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The dynamic antigen landscape of a progressing tumor could also account for the differences
seen in such studies. Spontaneous immunoselection of dominant epitopes remains a subject of
relevance, as many studies have shown that multiple metastatic nodules in the same cancer patient may
show a progressive loss of tumor-associated antigen:MHC complexes with time.21-23 It is thus crucial to
avoid discounting the observation that tumor heterogeneity, especially in advanced cancer patients, can
result in a diverse T-cell antigenic repertoire and how the limited pool of known antigens cannot
logistically reflect the complexity of this larger antigen burden seen in such patients. Our current
approaches to tumor vaccine therapy as well are simply too selective of a strategy to prevent tumor
growth and this is largely due to an assumption that every tumor cell shares a common antigen and does
not account for tumor heterogeneity and capacity for epitope selection with time.24
Already, there is truly no consensus on evaluating unknown or undefined Ag and research
efforts have recently been directed towards biophysical phenomena associated with early activation
signals such as intracellular receptor domain phosphorylation or calcium flux, among others, since they
can be assessed qualitatively and limit the need for specific biomarkers. Surface plasmon resonance,
quartz crystal microbalances, cantilever-based microarrays, and field effect transistors are among a wide
range of technologies with accelerating scientific development over the past decade with viable
alternatives to measure biomolecules associated with various cellular outputs resulting from cellular
phenomena such as an immune activation.25-28 Interestingly, the number of published journal articles
including the terms “biosensor” or “lab on a chip” have enjoyed an exponential increase over the years,
representing a keen interest in point-of-care diagnostics and its applicability to immunomonitoring.29
The majority of such methods rely on amplification of biochemical signals arising from exceedingly
small numbers of cellular subsets, such as activated CD8-APC pairs in our study, which would
otherwise be largely undetectable.
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Thus, it is more than evident that our strategies of monitoring responses need to be directed
towards partially or undefined antigens, such as assessing cellular responses to tumor-cell lysates,
modified tumor cells, or even DC-tumor cell fusions. The large variety of antigens may differentially
induce adaptive immune responses, including both the humoral and cytotoxic domains, to help decipher
a patient’s response. It was previously proposed that a limited number of antigens in a tumor cell-lysate,
or other composite antigen preparations, should at least be characterized in order to monitor specific
components, though we believe the relevance of identifying such antigenic compartments remains
debatable and subject to change with each assessment. 30-32
Summary of Background and Specific Aims of this Study
Much scientific insight has been gained since the 1980s in understanding T-cell activation via
the T-cell antigen receptor complex (TCR) and its downstream signaling effects.33-35 We now
understand that activation depends on the careful interplay of early signaling cascades via
phosphorylation, intra- and extracellular ion shifts, cytoskeletal reorganization, and eventual gene
transcription of activation cytokines, such as IL-2.36-39 Despite our sophisticated mechanistic
understanding, there is no reliable method of assessing the induction or augmentation of a patientspecific, tumor-directed T-cell response.31 Current laboratory efforts seek to assess T-cell activation by
means of biochemical changes such as cytokine secretion, cell surface markers, clonal expansion,
tetramer- or dextramer-positivity, and even apoptosis readouts. However, the scope of clinically
relevant, identified cancer epitopes, utilized as probes in such assessments, remains narrow since such
readouts are largely confined in potential on two fronts: the limited range of employable antigens (Ag)
and the unique and dynamic nature of tumor-associated antigens within each patient.30,40,41 In malignant
melanoma for example, antigens such as MART-1 that are common to even normal tissues are used in
crude assessments to essentially guess the level of CD8 anti-tumor responses. The clinical utility and
translational potential of our established antigen libraries are astounding imperfect, representing both a
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need for increased standardization efforts and the exploration of newer strategies to keep pace with
the clone-specific responses of each patient.40-42
Our study seeks to introduce a novel readout on the totality of an immune response to antigens
that need not be defined, a potential turning-point in the current strategies used to monitor patient
responses to therapies ranging in context from cancer, to autoimmunity, to vaccine therapy. The target
of our study is to develop novel approaches to clinically applicable immune-monitoring by eliminating
the reliance on a limited number of shared antigens to paradoxically address the complex and everadapting repertoire of immunogenic epitopes encountered by a host’s immune system. Our strategy
seeks to rapidly and collectively assesses CD8 T-cell reactions to sets of Ag that have been internalized
and processed by autologous antigen-presenting cells (APC), with direct translational relevance to
assessing the sets of patient-specific antigenic responses, regardless of their actual identities. We believe
this approach is extremely useful in monitoring real-time T-cell activation following introduction to
antigenic stimuli.43-47

Materials, Methods, and Approach
Our study seeks to demonstrate a system that characterizes T-cell activation from detectable
extracellular proton flux via spectrophotometry using a pH-sensitive fluorescent dye, within polyclonal
and antigen-specific contexts. It has been shown in previous literature that 8-hydroxypyrene-1,3,6trisulfonic acid (HPTS) is a photo-activated multivalent molecule whose fluorescent emission spectrum
varies sensitively with pH changes.48-50 The compound is nontoxic and not perturbic to cells due to its
inability to cross the membrane lipid bilayer, and its point emissions, which are reported ratiometrically,
correlate well to the proton concentration of a solution in several studies.51-56 We anticipate that this
method, which represents an indirect method of proton “capture”, will serve as a conceptual validation
of an alternative approach to assessing T-cell reactivity and support the development of downstream
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strategies for monitoring T-cell responses directed towards undetermined populations of antigens.
Our approach is one of the simplest and most cost-effective methodologies yet proposed in assessing Tcell activation, and maintains a unique level of novelty and innovation, and promises to bring us closer
to earlier and more effective assessments of patient treatment responses to help navigate clinical
decisions.
Polyclonal T-cell stimulation monitoring
Spleens were obtained from a 8–week-old female C57/BL6 mice (Taconic Biosciences, NY,
USA) and splenocytes were isolated though grinding and centrifugation of filtered splenic tissue in
RPMI medium supplemented with antibiotics and 10% fetal bovine serum. Contaminating red cells
were eliminated via treatment with ACK lysis buffer, followed by gradient centrifugation for
purification using a Lympholyte-M protocol (Cedarlane Labs, Canada). Cells were counted, from which
CD8 T-cells were purified using a negative selection EasySep protocol (Stem Cell Technologies,
Canada). Cells were stimulated via 1uM anti-CD3e mouse antibody (eBiosciences, CA, USA) and
plated into 96-well plates preloaded with 0.001M (in normal saline) of photoacid (8-hydroxypyrene1,3,6-trisulfonic acid; Sigma-Aldrich, MO, USA) at indicated cellular concentrations. Spot emission
assessments were taken at 2-minute time intervals for 30 minutes at excitation and emission
wavelengths of 405nm/445nm and 520nm respectively using a Spectramax Photometer and SoftMax
Pro Software (Molecular Devices, CA, USA). The point emissions are reported as mean ratiometric data
corrected for background noise as determined from non-photoacid containing wells.
APC:T-cell Couplet Formation and Imaging Flow Cytometry
An Amnis ImageStreamXMark II fitted with 4 lasers (405nm, 488nm, 642nm, and 785nm) was
used for imaging 60x magnification. A minimum of 1000 images were collected following mixing and
centrifugation of the Ag-presenting cells (APC) and T-cells at a 2:1 ratio for 60 seconds at 4˚C
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(Eppendorf, NY, USA). Gating strategy is similar to a previous study, with a focus on FITC, BV421
double-positive populations.57 Couplets were chosen due to good quality and resolution.

17
Antigen-specific Assessments
Utilizing the well-established murine OT-1 system, naïve 8-week-old female OT1/RAG2(-/-)
mice (specific for a chicken ovalbumin peptide fragment 257-264 presented by the MHC class I
molecule H2-Kb) and age-, sex-matched C57/BL6 (Taconic Biosciences, NY, USA) were sacrificed,
underwent splenic harvest, and CD8 negative isolation protocols as described above. Bone marrowderived dendritic cells (BMDC) were isolated from age and sex-matched C57/BL6 via an established
protocol using mouse-GMCSF (eBiosciences, CA, USA) and were incubated with either SIINFEKL
(OVA(257-264)) or control EIINFEKL (eBiosciences, CA, USA) at 1uM for 4 hours on day 7. OT1derived CD8 T-cells were incubated at 37˚C and combined with day 7 BMDCs at a concentration of
1E6 cells/mL and 2E6 cells/mL (1CD8:2APC), respectively. Titration experiments utilized identical
configurations of peptide-pulsing doses and OT1 responder cell dilutions with control C57/BL6 CD8s,
and vice-versa. The combined DC/T-cell suspension was spun (Eppendorf 5810R centrifuge, 1 minute,
4˚C, 1650rpm) and lightly resuspended to maintain APC-CD8 interactions. The spatial orientation of
conjugated APCs and CD8s was confirmed from an Amnis® imaging flow cytometer (Figure 2, EMD
Millipore, MA, USA). The centrifuged solution was aliquotted into black Costar 96-well plates (Fisher
Scientific MA, USA) into a final concentration of 0.001M HPTS (in normal saline) and subjected to
spectrophotometric analysis as mentioned above.
For parallel experiments with human cells, we utilized Day-7 blood monocyte-derived dendritic
cells (DCs) from HLA-A2 normal donors, which were either loaded overnight at 1uM concentration
with a MART-1-derived 26-mer “long” peptide (MART-115-40 peptide
KGHGHSYTTAEELAGIGILTVILGVL, “MART-1 LP”) which requires intracellular processing to
expose the immunodominant MART-126-35 peptide ELAGIGILTV, or with the 26-35 peptide itself for
4-6 hours prior to assessment, dubbed “short” peptide (MART-1 SP). A second melanoma-associated,
HLA-A2-restricted peptide derived from the gp100 protein (gp100154–162 KTWGQYWQV) acted as a
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negative control. Responder cells included either the human MART-1-specific TCR transgenic
CD8+ clone DMF5 (recognizing MART-127-35, a kind gift of John Wunderlich, NIH/NCI) which were
defrosted and restimulated with IL-2 one day prior to use, or naturally-occurring MART-126-35–specific
T-cells expanded from normal donors as described below. Titration experiments utilized identical
configurations of peptide-pulsing doses and naïve CD8 responder cell dilutions from the same donor.
MART-1-reactive CD8 Expansion
Blood was collected from HLA-A2 restricted donors and subjected to Ficoll gradient purification
and washing, according to a previously-established protocol to yield peripheral blood mononuclear cells
(PBMCs) which could be passed over a microfluidic chamber to convert blood monocytes to monocytederived dendritic cells by “plate passage”.58-60 PBMCs were divided into appropriate separate groups
from which either APC populations or CD8+ responder cells could be derived as previously described.
For plate passage, 25x106 PBMCs in autologous plasma were pre-incubated on a flow chamber plate for
1 hour. The cells were then removed from the chamber, which was then connected to a syringe pump
and the cells were passed through the chamber under flow conditions. Plate-passed PBMCs were
combined with MART-1 long-peptide (1uM) and responder CD8 cells at a ratio of 1 PBMC:1 CD8
under an assumption that the former consists of a 10% monocyte population. These cells were then cocultured in 12-well plates and were fed IL-2 (12.5 u/ml final) and IL-7 (5 ng/ml final) on day 3 and
every 3 days until day 9, when they were harvested and stained for MART-1 specificity utilizing
dextramer staining. For dextramer-based characterization, cells were resuspended in 50ul FACS staining
buffer and 10ul of each dextramer (Immudex, Denmark, Sweden) added to the tube. Cells were mixed
and incubated at room temperature for 10 minutes in the dark. CD3 and CD8 antibodies were then
added and the cells incubated at 4 degrees for an additional 20 min. Cells were washed and spun and
resuspended in FACS buffer containing 7-AAD for live/dead discrimination and analyzed on a
Stratedigm 13L flow cytometer (Stratedigm, San Jose, CA). For titration experiments additional naïve

19
donor CD8 cells were isolated from the identical donor on the same day. In the event that dextramer
positivity indicated that initial expansion was inadequate, a reboosting procedure was implemented,
similar to a previously established protocol.61 Cells were boosted with gamma-irradiated and peptide
loaded PBMC populations and supplemented with IL-2 and IL-7 as described above and reassessed at
day 9 post-boost for clonality and expansion levels via dextramer-positivity.
Correlation studies with Calcium Flux
Intracellular calcium was measured as described previously.62 Negatively-purified Tlymphocytes were incubated with Indo-1-AM (Life Technologies, MA, USA) at 1uM dissolved in 20%
Pluronic F-127 and dimethylsulfoxide for 45 min at 37 °C with limited light exposure and washed
subsequently prior to murine CD8-PerCP-Cy5.5 staining (eBiosciences, CA, USA). Day 7 murine
BMDCs, which were pulsed with antigen peptides (either SIINFEKL or EIINFEKL) for 4 hours at
37°C, were stained simultaneously with CD11c-FITC and subsequently washed. Human correlates were
stained with CD11c-PerCP-Cy5.5 and CD8-FITC. Cells were placed on ice prior to flow cytometry
(LSRII, Becton Dickinson NJ, USA) and warmed to room temperature via water bath immediately prior
to mixing at 2:1(APC:CD8) concentrations. The cell mixture containing BMDCs and OT-1 CD8+ Tcells were centrifuged and lightly suspended prior to sample loading into the flow cytometer. Relative
intracellular calcium concentrations were determined by the ratio of violet:blue (420:510 nm)
wavelengths. Data is shown as a median ratiometric emission for Indo-1 for the time interval following
conjugate formation. Raw data were analyzed with FlowJo software via median kinetic signal
monitoring (Treestar OR, USA).
Murine Tumor-Responsive Model and In Vivo Fluorometric Assessments
Tumor-bearing C57/BL6 mice underwent six, semi-weekly “murine extracorporeal
photopheresis” (m-ECP) treatment sessions, occurring on Day 10, 13, 16, 19, 22, and 25 following
tumor inoculation with 105 YUMM melanoma cells into the right flank. For each treatment session,
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PBMC were collected from whole blood via retroorbital venous capillary draws and subjected to
gradient centrifugation for purification using a Lympholyte-M protocol (Cedarlane Labs, Canada).
YUMM cells were trypsinized (Trypsin/EDTA, 0.25%) and harvested from cell culture, washed, and
subjected to 200nM 8-methoxypsoralen (UVADEX®) for 20 minutes, followed by 4J of UVA
irradiation. Purified PBMC in autologous plasma were pre-incubated on a flow-chamber plate for 1 hour
with PUVA-treated YUMM cells. The cells were then removed from the chamber, which was then
connected to a syringe pump. This mixture of irradiated tumor cells and PBMCs was passed over a
microfluidic chamber to convert blood monocytes to monocyte-derived dendritic cells by “plate
passage”.58-60 The flow conditions were uniform during the plate passage step (0.49 mL/min) and
washed afterwards at higher flow rates (1.49 mL/hr) with fetal bovine serum. Plate-passed cells were
collected, washed, and spun and resuspended in PBS, before being reintroduced systemically via
retroorbital injection. Tumor volumetric measurements were performed using precisely-calibrated
calipers prior to each treatment.
Days 16, 22, and 25 involved in vivo fluorometric assessments during which a mouse was
sacrificed from both groups (control and “m-ECP”), each undergoing CD8 negative selection
purification via splenic and lymph node harvests as described earlier. YUMM tumor cell lysate was
obtained by pelleting 20 x 106 cells in PBS (2-4 x 106 cells/mL), and subjecting this pellet to four freezethaw cycles by alternating liquid nitrogen and 37°C water bath treatments. Cells were sonicated for 15
seconds at 38% amplitude (Teledyne Tekmar, Ohio, USA) to rupture cell membranes. Cells were spun
at 12,000g for 20 minutes at 4°C to remove cellular debris. Supernatants were collected and stored at 20°C, before being administered to day 7 murine BMDCs, isolated using the aforementioned protocol,
for 24 hours. Lysate-pulsed BMDCs were then combined with purified CD8 T-cells of the control- and
treatment-group mice via centrifugation, and emission patterns were collected every 2 min for 60 min
using the protocol described previously for antigen-specific experiments.
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Results
Detectable Polyclonal Activation with Cellular Limits
Polyclonally activated CD8 T-cells demonstrated a sustained and consistent higher emission
intensity than unstimulated cells. This is depicted graphically in Figure 1. This activated pattern of
emission extends in sensitivity from ~104 cells down to ~10 cells per well (p<0.001) with detection
limits seen in 105 to 106 cells per well (p>0.05). A somewhat noticeable decrease in activated intensity is
also noted extending from 102 to 104 cells. Figure 1 depicts these results by indicating mean emission
intensities with plotted standard error bars.
Observable Antigen-Specific Activation of murine OT1 CD8+ Responders.
Following DC/CD8 co-culture and centrifugation-driven dimer formation (Figure 2), CD8
stimulation via antigen-specific and antigen non-specific peptide-pulsed dendritic cells (BMDCs) was
evaluated. At 1uM peptide loading, SIINFEKL-presenting DCs are capable of eliciting higher
fluorescence signals than control EIINFEKL-presenting cells when interacting with specific OT1 CD8+
responder cells (Figure 3a). This observation was significant for all OT1 cell dilutions (diluted in
C57/BL6 negatively-purified CD8s) tested, including 10% and 1% values. Upon pulsing with 10-fold
less peptide (0.1uM), similar results were observed (Figure 3b).
When APCs are pulsed with a peptide concentration of 0.01uM, higher emission signals are
observed in responder dilutions of 100% and 10%, but not seen in 1% populations (Figure 3c). At the
lowest titration level of 0.001uM peptide, significant difference is only seen at the 100% OT1 responder
level, but lost at the 10% and 1% levels. These data indicate that Ag-specific T-cell activation can be
monitored effectively utilizing the pH sensitive dye at physiologically relevant peptide and APC to Tcell concentrations.
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Conjugate Formation and Detectable Activation of Human MART-1-specific T-cells
Utilizing human DC loaded initially at 1uM of peptide, conjugate formation and T-cell
stimulation assays were carried out with a MART-1-specific human CD8+ T-cell readout line to
confirm antigen-specific APC-CD8 interactions. Figure 4a illustrates that significant differences were
seen when plate-passed cells, a source of 10-12% dendritic APC, are incubated with either unprocessed
(26-mer) and processed (10-mer) MART-1-derived peptides (LP and SP, respectively) versus control
gp100 peptide, when these APCs are complexed with a 100% specific DMF5 responder cells. DMF5 is
a MART-1-specific TCR transgenic CD8+ clone (recognizing MART-127-35) which should respond in
an Ag-specific manner following stimulation with DC either surface-labeled with the 10-mer MART-1
peptide or which had processed and presented the 26-mer “long” peptide. Significant differences are
noted between emissions observed following conjugate formation between DC and T-cell (black bars)
verses cells passively mixed in adjacent wells (grey bars). Dextramer staining (Figure 4b) confirmed a
high percentage of dextramer positivity for the DMF-5 line utilized in these assays. Interestingly,
MART-1 SP conjugation had the widest difference between conjugated cells than unconjugated passive
interactions, perhaps as a result of the higher density of specific peptides presented on the cell surface
following exogenous loading of pre-processed, form-fitting peptides. Nonspecific (gp100) peptideloaded cells were unable to establish notable signal differences from baseline, even with DC/T-cell
complexation.
Detectable Antigen-Specific Interactions with Naïve Expanded CD8 Responders
Since normal human donors have an unusually high frequency of naïve, MART-1-specific
precursors in their blood, it is possible to derive Ag-specific T-cells directly from normal HLA-A2
donors which can act as fresh Ag-specific T-cells for stimulation assays.61,63 Separate expansion trials
were accomplished utilizing normal donor blood as a source of naïve T-cells as described in Materials
and Methods. Following 1-week exposure of CD8 T-cell populations to MART-1 peptide-loaded DC,
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successful expansion of MART-1-specific T-cells was accomplished from all donors. MART-1
dextramer positivity of the T-cells was confirmed following expansions, which resulted in T-cell
populations in the 0.9% to 21.1% range.
Staining for the most successful expansion, 21.1%, is shown in Figure 5a. Each of the three
expanded T-cell populations was then utilized as responder T-cells in DC stimulation assays, which
mirrored those, previously carried out on the DMF5 transgenic line experiments. In each trial as shown
in Figure 5b, conjugated pairs showed notable increases in emission signal over control peptide-loaded
DC, consistent with antigen-specificity. One of these expansions successfully generated a dextramerpositive population of 2.3% and the expanded T-cells were used or diluted to increasingly lower specific
T-cell ratios (1.2%, 0.2%, and 0.02% respectively) with autologous, non-specific T-cells. At all specific
T-cell ratios tested, T-cell activation and fluorescent emissions were higher in cells stimulated with
specific MART-1 loaded DC compared to control gp100, with the exception of two trials (0.2% and
0.02% dextramer-positive groups). These observations indicate that specific T-cell populations at levels
as low as 90 per 10,000 in peripheral blood could be amenable to this analysis. The lowest MART-1
naïve CD8 expansion group was also capable of yielding detectable differences in calcium signaling by
means of intracellular calcium flux (Figure 7). To look at this data as a whole and determine whether a
relationship exists between mean fluorescent differences and antigen specificity, a regression plot was
developed (Figure 6). Mean emission differences between Ag-specific and –nonspecific differences for
the MART-1 expansion assessments are summarized and demonstrate a linear correlation to dextramer
values, with few notable statistical outliers, reasons for which are elaborated upon in the “Discussion”
section below.
Significant Differences in Emission Intensity using Unknown Antigens as Probes in an Animal Model
Mice from control and treatment groups were analyzed at three separate time points of six total
treatments. When subjected to APCs harboring tumor cell lysate antigens, CD8s from the treatment
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group revealed higher emission signals compared to controls for all assessments (Figure 8). The
largest difference was seen during the earlier half of scheduled treatments. There are notable
fluctuations seen with the emission patterns of the control group, though this group’s T-cells were
consistently less ”reactive” for all time points. It is not until the final treatment (Day 25) that a
significant difference in tumor volume is clinically observed between the groups for the remainder of
the experiment.
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Conclusion
The ability to simply and accurately quantitate the upregulation or downregulation of T-cell
based responses has vast implications for treatment of T-cell mediated diseases and vaccination-based
targeting in cancer. Since there is no longer a need to follow only defined Ags, the use of dynamic
antigen sources such as cell lysates or disease-associated whole proteins defined by personalized
genomic sequencing allow potential treatment monitoring against a panoplyPolyclonally activated of
T-cell relevant Ags. This capability is especially relevant within the context of immunotherapy, as each
patient engages to his or her own unique array of tumor-associated antigens presented via class 1 major
histocompatibility complexes (MHCs) to clone-specific T-cell receptors. Our study provides evidence
advocating for a shift in clinical readout strategies to assess the level of global TCR engagement in a
host and a capability to sensitively discriminate between specific and nonspecific T-cell stimulation by
APC. We established this with a rapid assay in murine and human antigen systems via
spectrophotometry. Due to the reliance on an extracellular analyte, our strategy is capable of detecting
signals deriving from rare subsets of cells, that are amplified extracellularly to increase detection
capability down to levels of approximately 10 polyclonally activated cells, 0.001M peptide-pulsed
APC:CD8 conjugates, and ~90 antigen-specific T-cells out of 10,000 unpurified donor PBMC within
our MART-1 system. Although the latter sensitivity may be attributable to the higher number of
stimulating APCs in the unpurified expansion samples, the translational capability of utilizing
unpurified patient PBMC for routine TCR engagement assessments is conserved.
The underlying motivation of our fluorometric approach is to overcome the severe limitations
that exist for monitoring Ag-specific T-cell responses in cancer and autoimmune therapy, particularly
attempts to quantify the complexity of an immune response based on limited set of probes. 64-67 As
mentioned previously, current favored strategies rely heavily on tetramer or dextramer positivity and in
vitro re-stimulations using APC pulsed with defined peptide epitopes in an attempt to quantify the
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degree of a patient’s immune reactivity and correlate to clinical outcomes. Such approaches to
assess tumor immunity often rely on following responses only to established tumor antigens, many of
which are shared with normal tissues (i.e. MART-1, gp100, prostate-specific antigen), and have failed
repeatedly due to the dynamic expression of tumor-specific neo-antigens and response kinetics of an
ensuing immune response. The complexity, cost and reality that many diseases do not possess a fully
characterized library of antigens renders the “single-antigen, single-readout” a currently intractable
challenge. The rate of tumor mutation heterogeneity renders these methodologies, which need to
uncover MHC-restricted epitopes at nearly every phase of treatment, rather impractical across virtually
every tumor type. 68-71 In addition, bona fide immune responses leading to tumor regressions often have
not correlated with T-cell responses against the limited number of Ag followed in clinical trial,
indicating that targeting and monitoring is neither practical or expected to yield satisfactory clinical
outcomes. 72-74 Yet another inconsistency in the field of immunological monitoring is determining what
an appropriate threshold would be for a “positive response”, as this is currently unknown and amounts
to relative estimation. 75-78
Here, we present an approach that provides a collective assessment of immune reactivity,
qualitatively and quantitatively, that can provide prompt and accurate clinical information. The model
antigen systems utilized in our study undergo the same internalization, processing, and presentation as
do the distinct tumor antigens and are detectable at frequencies that rival clinical MHC dextramer
values.79 Moreover, at steady state, a single cell is capable of producing ~108 protons per second, a rate
that can be raised between ~10 to 100%, depending on the method and degree of receptor stimulation. 11
By utilizing an approach that detects such extruded protons, our system may also possess a signal
intensity that correlates to the presence of relevant polyclonal antigens, regardless of their identity. For
these reasons, our proposed strategy has major ramifications for the field of immune-monitoring as it
shifts the focus towards quantifying the total reactivity of clonal T-cell populations.
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The utility is understood considering the numerous potential immunotherapeutic and cancer
vaccine agents are currently being trialed, including immune checkpoint inhibitors and DC-based
vaccination strategies. But with limited options of immune-monitoring tools for evaluation, oftentimes
researchers are forced to use only gross assessments such as tumor size or symptom amelioration to
define therapeutic benefit. Monotherapies such as extracorporeal photopheresis (ECP), used for both
cutaneous T-cell lymphoma and autoimmune diseases such as graft-versus-host diseases, could benefit
from such an analysis, as treatment-resistant cases exist could benefit from earlier shifts in treatment
course, particularly since ECP has uniquely shown both immunogenic and tolerogenic effects. 58,80-83
Several existing technologies are capable of sensing proton differences in solution, including pH
microelectrodes, pH radiolabeled and fluorescent probes, and silicon field effect transistors. 84-88
Previous technologies looking at proton flux within the context of activated T-cells include lightaddressable potentiometric sensors (LAPS) and chemically-modified field effect transistors (CHEMFET), based on similar semiconductor-based technologies. 11,45 Both showed tremendous sensitivity in
detecting proton flux from cells following soluble stimulatory factors and have shown more promise
than traditional assays. 89 Though Stern’s one-dimensional CHEM-FETs showed tremendously sensitive
detection capabilities (~200 cells within 10 seconds of a stimulus), issues commonly acknowledged with
CHEM-FETs includes inter-device manufacturing variations potentially blunting sensitivity, temporal
deterioration of device performance, inconsistent calibration efforts and of course overall expense. 12
Moreover, such technologies have yet to evaluate real-world cellular interactions vital to CD8 activation
such as the use of a patient’s autologous dendritic cells as activation agents, not only a crucial wing of
modern cancer immunotherapy, but also a promise to monitor patient responses to immunomodulatory
treatments using personalized antigens and responder cells. 90-94 Our fluorometric approach therefore
potentially offers a simple and low cost alternative with respect to many of these aforementioned
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challenges as it enables the local and rapid detection of extracellular proton flux without a
manufactured nanodevice, allowing monitoring of APC:CD8 interactions in a variety of clinical
settings.
Benefits from the fluorometric proton flux immunoassay itself include its simplicity and
versatility, which enable a considerably more rapid readout than current assaying protocols, and allows
for the combination of readouts from numerous techniques to evaluate whether clinical correlations can
be predicted more robustly and with increased accuracy. Further studies will naturally be crucial to
evaluate whether clinical correlations can be drawn from fluorometric proton flux data, particularly
since evaluation guidelines are unclear in regard to using sets of undefined antigens, such as tumor cell
lysates. 31,42,95 Unknown antigens, which are dynamic in frequency and vary between patients and even
within a patient’s tumor itself, are the key to providing insight to the competency of any
immunomodulatory treatment. The complexity of tumor associated antigens are undeniable and matched
by the inner workings and sensing capabilities of an immune response, neither of which can adequately
assayed or understood using the sparse repertoire of known cancer epitopes. The significance of our
study lies in the validation of an early-stage, alternative strategy and establishing the potential for
downstream advances in immunological monitoring that will undeniably translate into more effective
treatment response prediction models, tailoring of clinical decision-making, and increased
“personalization” as we approach the unique case of every patient.
Drawbacks of this Study
By no means is our approach the solely appropriate one for discriminating overall TCR
engagement. Our methods are a rudimentary strategy that seeks to provide conceptual evidence for an
approach that would yield clinically meaningful data in a variety of immunogenic and immunotolerant
settings. While it is established to correlate with T-cell activation, extracellular acidification ultimately
represents a single facet of a complex set of reactionary biochemical changes. With respect to the
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materials and protocols, HPTS may also not be the best indicator of extracellular [H+] as other
photoacidic fluorescent agents exist. 96,97 Additionally, there are other agents that can help determine the
analyte levels resulting from other cellular processes apart from cellular acidification. Calcium flux,
which is investigated in this study, can be studied with a fluorescent microscopic or plate-reader
approach, the latter allowing for increasingly high-throughput studies.98 A study was successful at using
functionalized glass slides to assess short-term cytokine secretion (IFN-γ, IL-2, TNF-α) and cytolytic
activity in a high-throughput fashion using fluorescent imaging of the cell populations.
Our experiments fell short of displaying consistent emission intensity baselines, which may be a
product of inconsistent manual solution titration. The various baseline levels were hedged by the
comparison of the emission changes associated with an activated population from a control, which we
assumed and proved would be related to the reactivity, or dextramer-positivity, of a T-cell group. The
inconsistent background in our experiment renders modeling the kinetics of proton extrusion rather
difficult and is certainly a potential area of improvement.
Future Directions
Metabolic Phenotyping as Insight into Activated Cell Populations
Our presented system, though far from completion, lays the framework for a collective effort to
discount the need for identifying immunodominant epitopes for each patient’s tumor. Though
rudimentary, several elements of our approach can be improved upon and standardized for a method to
collectively assessing a subject’s T-cell reactivity to presented antigens. A variety of different
procedures can exist when focusing on biophysical phenomena associated with cellular activation. The
energy-consuming nature of such a process entails a concatenation of measurable chemical changes that
occur both inside and outside of the activated cell. In addition to the extracellular proton flux or
intracellular calcium flux investigated in this study, approaches can also seek to characterize metabolic
events such as oxygen consumption rates (OCR) or carbon dioxide generation from such events. OCR
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can be readily measured and is shown to be higher in CD8 cells than CD4s upon stimulation via a
preference for aerobic glycolysis.99 Looking at ratios that relate oxygen consumption or carbon dioxide
generation can even indicate which catabolic pathways such metabolically reprogrammed cells
preferentially utilize. Theoretically, recording the basal oxygen consumption of a cell population and
assessing for differences following antigen stimulation, or the admixture of responder cells, could shed
light on the overall metabolic profile of intracellular events that follow TCR engagement.
Along similar lines, assessment of the byproducts of cellular respiration or other aerobic
metabolic processes within the activated lymphocyte can be another wing of reassurance with which to
approach the issue. Studying these key tenets of the metabolic reprogramming that occurs to provide the
materials for biosynthetic processes will shed light on discriminated an engaged group of cells from a
nonreactive counterpart. As activated populations are more oxidative, they tend to be associated with
greater levels of reactive oxygen species and elevated production of glycolytic compounds such as
lactate. Such processes are necessary for cellular survival, growth, and proliferation, with the existence
of data indicating that stimulation can also increase the observable median cell size in T-cells with time.
The signaling pathways that result in the distinct metabolic signatures associated with lymphocytic
activation can be explored using probes aimed at assessing compounds seen along the entire spectrum of
activated T-cells. This allows us to study differences in the reprogramming that occurs in activated
populations and directs our attention to downstream effects of an antigen-specific interaction, rather
than focusing on the molecular structure or identity of that stimulus. Our strategy therefore hedges
against the uncertainty associated with the unique immunogenic stimuli in each patient by reporting
instead on the downstream features of an activated receptor that can be observed independent of a
tumor’s antigen expression profile.
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Improving Detectability via Targeted Agent Delivery
The TCR:MHC interactions that occur at the immunological synapse can dictate the fate of an
effector cells. The synaptic complex consists of a variety of costimulatory receptors and adhesion
proteins, on both the T-cell and APC, that can be targeted for an increasingly localized detection of
extruded electrolytes. It is established that targeted agent delivery is more effective for eliciting a certain
cellular response than systemic delivery. The impressive effects of targeted delivery can be understood
from mathematical modeling of the localized concentration gradients that occur at the surface of a
responder cell. The Laplace Diffusion equation can shed light on the paracrine effects of a APC on its
target effector by showing that the concentration of a secreted protein or molecule will decrease
inversely with radial distance, with the highest concentration noted at its surface.100 In a paracrine
modeling system, in which a cell is secreting protein factors to another, we can observe that the gradient
on the targeted cell surface is exponentially greater than the one found in solution. Thus, when an APC
and T-cell interact at the TCR:MHC complex, it is extremely important for the two cells to do so as
closely as possible in order to increase the release and absorptive capacities of both cells.
Along these lines, a similar assumption can be made for extruded cellular analytes deriving from
a stimulating immunological synaptic interaction. For our study, the protons extruded by membranebound channels and pumps provide a conceptual framework for enabling detection as close as possible
to the T-cell surface as possible via nanoscale vehicles. Liposomes are well studied platforms with ideal
chemical properties for the encapsulation of HPTS, a strongly hydrophilic substance that would
otherwise be relatively more difficult to load into the hydrophobic core of other alternatives.101 In
addition, liposomes also have a surface modifiable lipid bilayer, to which targeting ligands can be
conjugated and help with the navigation of such particles to specific targets.102 The formulation enables
encapsulation and sustained release of the loaded agent over time through a two-step approach in which
the internal polymer matrix is synthesized and entrapped within a liposomal shell structure that can have
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targeting elements conjugated to its surface. We hypothesize that targeting such elements to adhesion
molecules that participate peripherally in the TCR engagement process may provide a more sensitive
reading of the acidification or proton gradient emanating from the surface of an activated T-cell.
Our design for a murine prototype for such an endeavor would involve the conjugation of antiLFA1 (anti-leukocyte functional antigen-1, or anti-CD11a) antibodies to the surface of the liposomes
with the intent of targeting the T-cell receptor that interacts with the ICAM-1 (Intercellular adhesion
molecule-1) ligand on the surface of the dendritic cell. The formation of an immunological synapse
relies heavily on the dynamic characteristics of the secondary receptors and adhesion factors associated
with APC:T-cell crosstalk. Targeting this particular area with the nanoscale agents will allow for
localized delivery of our fluorometric indicator and a heightened sensitivity to the T-cell surface, where
the kinetics of proton release are highest and therefore the concentration gradient will be most
detectable. One obvious advantage is that such an approach will heighten the sensitivity of
distinguishing activated T-cells within a heterogeneous population of immune cells. Rather than relying
on the global acidification of a soluble medium, this approach allows us to report on the
microenvironment associated with activated lymphocytes during and after the process of antigenspecific priming. Another advantage of this approach would be in the ability to render time-lapsed
assessments for populations of cells to look for temporal trends that may indicate rapid rises in emission
patterns that could correlate to the stimulation of a certain cell populations. The nontoxic nature of the
approach could allow for longer and more comprehensive assessments of a patient’s immune cells.
A Label-free Approach to Antigen-Specific Responses via Nanoscale Semiconductors
An important hurdle to overcome from our various approaches entails the variability of baseline
fluorescent characteristics seen with every assessment. Though a variety of factors may be associated
with spectrophotometric approaches, such as the standard error associated with manual titration of
HPTS in solution, our approach hedged against such inconsistencies by standardizing conditions for
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each assessment and seeking the most ideal controls for each assessment. An incentive for
transitioning our approach using a device-based approach is attractive due to the standardized conditions
associated with a fabricated device that may be utilized several times for assessments from a particular
patient, rendering the baselines of comparison increasingly standardized and aiding with the
discrimination of significant changes in assessed reactivity or TCR engagement over the course of
treatment. One-dimensional materials, such as nanowires, can be implemented for many applications
such as the aforementioned “lab-on-a-chip” purposes. The unique electrical and surface-to-volume
ratios of such devices, render their clinical integration increasingly exciting.44 The top-down approach
of selective etching yields a high standard of manufacturing to the molecular-scale that can output
consistent clinically useful data.103 Additionally, such technology has advanced tremendously in the past
decade with more advanced techniques for chemical functionalization that allow utility to extend
beyond simple analyte measurements, but also can help with the biophysical elements of cellular
activation such as adhesion, morphology, and differentiation.104
A newer, optoelectronic approach was investigated aimed at rapidly detecting solution pH in
minute fluid volumes from a semiconducting nanodevice which showed a capability to measure the
absolute concentration of molecular analytes in real-time. However, this particular design was uniquely
deviant for the ability to calibrate each semiconductor using fluorescent, reducing inter-device
variability, and showing unprecedented success in monitoring continuous cellular metabolic processes.
In an experiment, Peretz-Soraka and colleagues were able to show real-time detection of pH changes
resulting from the metabolic activity of Jurkat cells upon the administration of glucose. This could have
tremendous consequences on our ability to identify metabolic signatures associated with antigenspecific activation with time and enables such studies to occur at the picomolar level.12 Interestingly, the
photoactive molecular species and chief sensing element of this highly-sensitive nanoscale
semiconductor is actually a derivatized form of HPTS conjugated to the surface of the device. Although
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the derivatized form possesses different functional groups, the study nevertheless points to the
heightened sensitivity of spectroscopic agents as effective reporters for clinically relevant cellular
processes. The capability to sensitively detect such information is extremely useful in the realm of
immunological monitoring as it provides functional and molecular correlates, helping clinicians
navigate the complexity of a patient’s immune response to decipher risks for tumor progression, organ
rejection, sepsis, or other life-threatening conditions prior to encountering clinically observable
symptoms.
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Figure 1. Polyclonal activation with cellular limits of assay detection and monitoring. Various
numbers of cells (indicated) were plated in single wells and subjected to 1uM anti-CD3e mouse
antibody for stimulation. Emission signals were collected for a 60-minute duration. Significant
differences are marked with an asterisk (p<0.001).
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Figure 2. Imaging flow cytometer depictions of APC:T-cell couplets formed after centrifugation
and light resuspension. Antigen-presenting-cells and T lymphocytes are labeled in CD11c-FIT and
CD8-Brilliant Violet 421 antibodies, respectively. Ch02 corresponds to FITC-labeled APCs and Ch07
renders BV421-labeled CD8s. The three couplets shown are representative from a single experiment.
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Figure 3. Fluorometric differences between Ag-specific and –nonspecific interactions in the OT-1
system. Such interactions occur following presentation by BMDCs via MHC class I H2-Kb within the
context of OT1/RAG2(-/-) mice. A) At 1uM peptide pulsing concentrations, SIINFEKL-presenting
DC:T-cell interactions following complexation emit at more significantly than EIINFEKL-based control
groups extending from 100% to 1% OT1 Responder CD8 cells. B) When peptide pulsing concentration
is reduced tenfold, this effect remains preserved throughout the OT1 responding cell titrations. C) At
0.01uM this significant differences are maintained from 100% until the 10%, but lost at a 1% OT1
responder level. D) The lowest titration showed a significant difference only at the 100% OT1 responder
level, with a loss of the effect for lower percentages of OT1 responders. Significant differences are
marked with an asterisk (p<0.001).
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Figure 5. Flow cytometry gating strategy and summary of overall expansion photometric data. A)
Cells are initially gated and isolated by 7-AAD negativity, indicating viability. Of the 7-AAD+ cells,
CD3+CD8+ double-positives are selected and focus is placed on the MART-1+ cells. B) An
amalgamation of successful MART-1 expansions utilizing plate-passed APCs is indicated, along with
their emission intensity differences when complexed with cytokine-generated dendritic cells presenting
either MART-1 “long” peptide or gp100 (form-fitting control) peptide. All pairs are significant with the
exception of the 0.2% and 0.02% dextramer group.
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nonspecific interactions in the MART-1 system. Values are standardized and based on dextramer
positivity, as determined by flow cytometry. A positive, linear correlation (R-squared=0.89) was
obtained with significance (p=0.0015) and minimal outlier values.
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Figure 7. Calcium Flux Correlation for 0.9% MART-1 Dextramer Population. A qualitative, yet
distinct signal is seen following conjugate formation, indicated with a blue arrow. SIINFEKL represents
an antigen-specific interaction which displays a higher magnitude and frequency changes when
compared to EIINFEKL, which is a much weaker, stimulatory interaction. Time in seconds.
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Figure 8. In vivo Fluorometric Assessments in an Animal Tumor-responsive Model. Our treatment
group (m-ECP) showed significant differences in emission intensity, or T-cell reactivity, compared to
our control group (PBS) prior to an observable clinical response. Treatment days are indicated with a
black arrow and assessment time points are indicated in red arrows. Error bars indicate standard error
measurements.
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